Related Experiment Video

Updated: Aug 7, 2026

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)
10:02

Event Related Potentials (ERPs) and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder (ADHD)

Published on: March 12, 2020

Methylphenidate transdermal system: In attention-deficit hyperactivity disorder in children

Vanessa R Anderson1, Lesley J Scott

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs
|June 23, 2006
PubMed

Insights

The methylphenidate transdermal system (MTS) patch effectively treats attention-deficit hyperactivity disorder (ADHD) in children. This ADHD treatment offers sustained drug absorption and significant symptom improvement with generally mild side effects.

Area of Science:

  • Pharmacology
  • Pediatrics
  • Neuroscience

Background:

  • Attention-deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in children.
  • Methylphenidate transdermal system (MTS) offers a sustained-release alternative to oral methylphenidate (MPH).
  • MPH is a central nervous system stimulant affecting dopamine and noradrenaline pathways.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of the methylphenidate transdermal system (MTS) in pediatric patients with ADHD.
  • To assess the pharmacokinetic profile of MPH delivered via the MTS patch.
  • To compare the effectiveness of MTS patches against placebo in managing ADHD symptoms.

Main Methods:

  • Utilized controlled trials involving children aged 6-12 years diagnosed with ADHD.
  • Administered MTS patches releasing MPH doses of 10-30 mg over a 9-hour period.
  • Monitored ADHD symptom improvement and recorded adverse events.

Main Results:

  • MTS patches demonstrated significantly greater improvements in ADHD symptoms compared to placebo.
  • Mean peak plasma concentrations of d-MPH were reached approximately 8 hours post-application.
  • Adverse events were comparable to oral MPH and predominantly mild to moderate in intensity.

Conclusions:

  • The methylphenidate transdermal system (MTS) is an effective and well-tolerated treatment option for pediatric ADHD.
  • Sustained drug absorption via MTS provides consistent therapeutic levels for ADHD management.
  • MTS offers a viable alternative for children requiring continuous MPH delivery for ADHD symptom control.

More Related Videos

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients05:48

The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients

Published on: June 12, 2020

Using Brain Activation (nir-HEG/Q-EEG) and Execution Measures (CPTs) in a ADHD Assessment Protocol13:09

Using Brain Activation (nir-HEG/Q-EEG) and Execution Measures (CPTs) in a ADHD Assessment Protocol

Published on: April 1, 2018

Related Concept Videos

Attention-Deficit/Hyperactivity Disorder01:30

Attention-Deficit/Hyperactivity Disorder

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings.
Transdermal Drug Delivery Systems01:18

Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...
Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...